House Members Want Greater Transparency on Drugs Reimbursement
Sixteen House members are asking three pairs of committee leaders to consider a bill they say would improve transparency of the business partnerships between the government and pharmacy benefit managers.
They say poor oversight of the reimbursement system puts a burden on taxpayers and greater transparency would improve the reimbursement system for generic drugs.
Reps. Doug Collins (R-Ga.) and David Loesback (D-Iowa) led 14 of their colleagues in drafting the letter, which voices support for H.R. 244, which Collins introduced and Loesback was an original co-sponsor of.
“The PBM industry is not well understood by many in Congress and the Administration and that is why we believe it is imperative for your committees to examine and consider putting the appropriate safeguards in place to ensure integrity in Medicare Part D, FEHBP and DoD TRICARE,” the members wrote in a letter to the bipartisan leaders of the Energy and Commerce, Ways and Means and Armed Services committees.
“Generic prescription drugs account for approximately 80 percent of drugs dispensed, but the reimbursement system for these medications is a mystery and it is incumbent upon us to conduct the appropriate oversight of this very large PBM industry to make sure taxpayers are not ‘footing the bill’ for generic prescriptions simply because the PBMs are not required to update the drastic and unpredictable fluctuations we have seen in the generic drug marketplace,” they write.
Click here to see the original article on the Morning Consult website.
Recent Posts
-
Senior Care Pharmacy Coalition Shares Comments with CMS Regarding Medicare Part D Restructuring Guidance: “Smoothing Provisions”
SCPC filed comments with CMS in response to their guidance on the implementation of the Medicare Part D restructuring portion of the Inflation Reduction Act (IRA).
-
Drug pricing efforts threaten ‘very existence’ of LTC pharmacies: reps
President Biden in his State of the Union address last week vowed to end “Big Pharma’s” grip on prescription drug pricing and cut costs for seniors and taxpayers by another $200 million.
But the president’s plans to expand his administration’s first-ever Medicare drug price negotiations could spell big trouble for the pharmacists who support seniors living in long-term care settings, advocates warned in response. -
President Biden Announces Desire to Cap Drug Prices for All Americans
In the State of the Union Address on March 7th, President Joseph Biden announced a proposal to expand the number of drugs targeted for annual price negotiations by Medicare and lower prescription drug costs for American families.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.